Rgenix is a privately-held clinical-stage biopharmaceutical company developing first-in-class drugs that target key pathways in cancer progression.

310 E 67th St, Suite 1-12‎ New York, NY
(646) 856-9261
Roger Waltzman

Roger Waltzman, M.D., M.B.A.

Chief Medical Officer

Roger is a Board-certified Medical Oncologist with over 20 years of experience supervising the delivery of complex oncology patient care and palliative medicine in teaching hospitals and developing new drugs in oncology and in malaria at large pharma.

Prior to joining Rgenix, Roger was the CMO/CSO for Napo Pharmaceuticals and Jaguar Health, developing first-in-class, FDA-approved botanicals as novel antidiarrheals. Roger spent over nine years at Novartis, most recently as Global Program Head responsible for early and late-stage development activities of antimalarials, including Coartem and two compounds in Phase 2 development, including generating a collaboration agreement with Medicines for Malaria Venture and the Bill and Melinda Gates Foundation. Previously, Roger was responsible for Global Clinical Development activities for several oncology compounds including the successful NDA filing of Jakavi and sNDAs for Tasigna and Gleevec.

For nearly 12 years, Roger worked as a clinical medical oncologist and clinical researcher at Memorial Sloan Kettering Cancer Center, Mount Sinai Hospital, and Saint Vincents Cancer Center, all in New York. He held academic positions as Assistant Professor in the Department of Medicine at Mount Sinai School of Medicine and New York Medical College.

Roger received his undergraduate degree magna cum laude from Brown University in Providence, RI with honors in American Literature. He also received his medical degree from Brown University School of Medicine and completed his internship and residency at Harvard’s Beth Israel Hospital in Boston, MA. He completed his fellowship at Memorial Sloan-Kettering Cancer Center in hematology and oncology. He graduated with an M.B.A. from Columbia University in New York.